The State of Asthma Research in the US Right Now
Asthma affects roughly 25 million people in the United States, and for a subset of those patients, standard inhalers and oral medications never quite get the job done. That gap between available treatments and real-world symptom control is where clinical research comes in. Across the country, academic medical centers, private research organizations, and pharmaceutical companies are running hundreds of studies aimed at everything from mild allergic asthma to the most stubborn severe eosinophilic cases.
The landscape has shifted noticeably in the past few years. Biologic therapies—medications that target specific inflammatory pathways rather than broadly suppressing the immune system—have become a major focus. Tezepelumab, known by the brand name TEZSPIRE, is now being studied in a Phase IIIb trial called TAPER to see whether patients who respond well to it can safely reduce their other maintenance medications. Eli Lilly is running a large study on brenipatide for adults with uncontrolled moderate-to-severe asthma. And just this year, AstraZeneca's triple-combination inhaler Breztri received approval for asthma maintenance in patients aged 12 and older, building on years of data from the KALOS and LOGOS trials.
What does this mean for someone with asthma? It means more options are being tested right now than at almost any point in the past decade. Research networks like the American Lung Association's Airways Clinical Research Centers and the NIH's asthma programs are actively recruiting across multiple states, from Texas to New York to Maryland.
What Kinds of Trials Are Out There
Not all asthma clinical trials look the same. Some test a new drug that has never been used in humans before. Others compare an existing medication against a new combination or dosing schedule. The trial phase gives you a rough idea of where things stand.
Phase I studies are small and focused on safety. They typically enroll healthy volunteers or, in some asthma cases, people with mild disease. The goal is to see how the body processes the drug and whether it causes unexpected side effects.
Phase II studies expand the pool and start looking at efficacy signals. Researchers ask: does this actually help asthma symptoms, and at what dose? Many of the biologic asthma treatments available today went through Phase II trials that enrolled between 100 and 400 participants.
Phase III trials are the large, registration-quality studies that drug developers use to seek approval. These often involve hundreds or thousands of patients across multiple countries. They compare the experimental treatment against placebo or an existing standard of care, and they measure outcomes like annual exacerbation rates, lung function changes, and quality-of-life scores.
Phase IIIb and Phase IV studies happen after a drug is already on the market. The TAPER study with tezepelumab is a good example—it asks a practical question that matters to patients: can I eventually step down from some of my other medications without losing asthma control?
Here is a quick comparison of the main trial types you might encounter:
| Trial Type | Typical Duration | Participants | What Is Tested | Key Consideration |
|---|
| Phase I | Weeks to months | 20-80 | Safety, dosing | Highest uncertainty; usually healthy volunteers |
| Phase II | Several months to 1 year | 100-400 | Efficacy, side effects | First real look at whether the drug works for asthma |
| Phase III | 1-2 years | 300-3,000+ | Confirmatory efficacy vs. placebo/standard care | Most rigorous; often multi-site |
| Phase IIIb/IV | 6 months to 2 years | Varies widely | Real-world use, long-term safety | Drug already approved; practical questions |
What Actually Happens When You Join
David, a 42-year-old teacher in Ohio, enrolled in a severe asthma trial two years ago. "I thought I'd be in a lab coat sitting in a hospital all day," he said. "Turns out most visits feel like a very thorough checkup."
Here is a realistic picture. After an initial screening visit—where the research team reviews your medical history, runs breathing tests, and confirms you meet the eligibility criteria—you will typically have a series of study visits. These might happen every two weeks at first, then taper to monthly or quarterly. Each visit often includes spirometry (blowing into a tube to measure lung function), a physical exam, blood draws, and questionnaires about your symptoms and quality of life.
Some trials require overnight stays, particularly early-phase studies. Others are entirely outpatient. You might be asked to keep a daily symptom diary at home, either on paper or through a smartphone app. The study drug could be an injection, an infusion, an inhaler, or a pill. If there is a placebo arm, you will be told upfront—informed consent is a legal and ethical requirement—and you will not know which group you are in until the study ends.
One thing that surprises many people: the level of attention you receive. "My regular doctor is great, but she has ten minutes per appointment," David noted. "During the trial, someone was tracking my peak flow every visit and calling me between appointments to check in." That kind of monitoring is built into the research process, and it can feel reassuring.
Compensation varies widely. Screening visits at some centers pay around $125 for time and travel. Full study participation can range from a few hundred dollars to several thousand, depending on the length, number of visits, and whether overnight stays are required. The BWH Asthma Research Center in Boston, for instance, has listed compensation in the range of $1,450 to $4,900 for different studies, though the exact amount depends on the specific trial protocol. Importantly, all study-related medical care, tests, and the investigational medication itself are provided at no cost to participants.
How to Find a Trial That Fits
The most comprehensive starting point is ClinicalTrials.gov, a database maintained by the National Library of Medicine. You can search by condition ("asthma"), location (your city or state), and status ("recruiting"). The site lists details about eligibility, study design, and contact information for each trial.
If you prefer a more guided approach, major research hospitals often have dedicated clinical trial navigation offices. The NIH Clinical Center in Bethesda, Maryland runs its own asthma studies and can be reached directly. The American Lung Association maintains a network of Airways Clinical Research Centers across the country, and their website lists actively recruiting studies.
For those searching online, phrases like "asthma clinical trials near me" or "severe asthma research studies [your city]" can surface local options. Some patients find trials through their own pulmonologist or allergist, who may be aware of studies at nearby academic centers.
Before you commit to anything, there are a few questions worth asking the research coordinator:
- What is the time commitment, including travel and at-home requirements?
- Will I need to stop my current medications during the trial?
- What happens after the study ends—can I continue on the treatment if it works?
- Who covers costs if there is a complication?
- Has an institutional review board (IRB) approved this study?
These are standard questions, and any reputable research team will answer them clearly.
Weighing the Tradeoffs
Joining a clinical trial is not for everyone. There is always the possibility that the experimental treatment does not work, or that you receive a placebo instead of active drug. Side effects, even in late-phase trials, are not always fully understood. The time commitment can be substantial, especially for studies with frequent visits.
On the other hand, participants gain access to treatments that may not reach the market for years. They receive expert medical monitoring at no cost. And they contribute to science that could change how asthma is managed for millions of people.
Sarah, a 34-year-old in Colorado with eosinophilic asthma, put it this way: "I had tried three different inhalers and still ended up in the ER twice a year. Joining a biologic trial was a leap of faith, but my exacerbations dropped to zero during the study period. Even if I got the placebo, the monitoring alone taught me more about my triggers than I had learned in a decade."
The National Institutes of Health and major asthma organizations emphasize that participation is always voluntary and that you can withdraw at any time. No one is locked into a trial against their will.
Beyond the personal benefits, there is a broader point worth considering. Every asthma medication on pharmacy shelves today—from albuterol rescue inhalers to the newest biologics—exists because someone before you volunteered for a clinical study. The American Lung Association's research network, the NIH's asthma programs, and the many pharmaceutical trials running across the country all depend on this quiet participation.
If you are curious, the next step is simple: look up what is recruiting near you, call the number listed, and ask your questions. There is no obligation, and simply learning what is available can open doors you did not know existed.
研究の知恵